SomaLogic, Inc., a leader in proteomics technology, reported recent business highlights and financial results for the quarter ended September 30, 2023.
- Revenue of $22.0 million, reflecting 14% year-over-year growth when excluding royalty revenue from NEB in the corresponding prior-year period
- Cash and investments of over $450 million
- Raising full year 2023 revenue guidance to $82 million to $85 million
- Management to host conference call today at 4:30pm ET
BOULDER, Colo., Nov. 08, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today reported recent business highlights and financial results for the quarter ended September 30, 2023.
“We’re pleased to report another quarter of solid execution, marked by commercial and operational discipline throughout the organization,” said Adam Taich, Interim CEO of SomaLogic. “Momentum is building in our business, as highlighted by increasing commercial activity and newly expanded content with our 11K SomaScan launch. We remain excited about our ability to consistently deliver results in the attractive proteomics market.”
Recent Business Highlights
- Announced plans to combine with Standard Biotools through an all-stock merger, creating a scaled and diversified leader in life science tools with an anticipated path to breakeven
- Announced commercial launch of the 11K SomaScan platform, giving researchers the broadest coverage of the proteome available for increased discovery of biomarkers and drug targets
- Announced the expansion of the Company’s agreement with Novo Nordisk to 2025
Third Quarter2023 Financial Results
Revenue for the three months ended September 30, 2023 was $22.0 million, a 47% decrease from $41.7 million in the corresponding period of 2022. Excluding royalty revenue from NEB in the corresponding prior-year period, revenue grew 14%.
Gross margin for the three months ended September 30, 2023 was 47.2% compared to 72.0% for the corresponding period of 2022. Excluding NEB royalty revenue from the prior period, gross margin increased 7.4% year-over-year as the result of increased price and product mix.
Research and development expenses decreased by $9.0 million. Selling, general and administrative expenses decreased by $25.6 million in the three months ended September 30, 2023, compared to the corresponding period of 2022. Transaction costs increased by $2.4 million for the three months ended September 30, 2023 compared to the three months ended September 30, 2022.
Net loss was $22.2 million for the three months ended September 30, 2023, or a loss of $0.12 per share, as compared to a loss of $32.9 million, or $0.18 per share, in the corresponding period of 2022.
Adjusted EBITDA was a loss of $20.1 million for the three months ended September 30, 2023, compared with an adjusted EBITDA loss of $30.2 million in the corresponding period of 2022. Cash, cash equivalents, and short-term investments were $453.8 million as of September 30, 2023.
2023 Financial Guidance
SomaLogic expects revenue for the full year 2023 to range from $82 to $85 million.
Webcast and Conference Call Details
SomaLogic will host a conference call at 4:30 p.m. ET on Wednesday, November 8, 2023, to discuss its third quarter 2023 financial results. Those interested in listening to the conference call should register online here. Participants are encouraged to register more than 15 minutes before the start of the call. A live and archived version of the webcast will be available at https://investors.somalogic.com/
About SomaLogic
SomaLogic is catalyzing drug research and development and biomarker identification as a global leader in proteomics technology. With a single 55 microliter plasma or serum sample, SomaLogic can run 7,000 protein measurements, covering more than a third of the approximately 20,000 proteins in the human body and twice as many as other proteomic platforms. For more than 20 years we’ve supported pharmaceutical companies, and academic and contract research organizations who rely on our protein detection and analysis technologies to fuel drug, disease, and treatment discoveries in such areas as oncology, diabetes, and cardiovascular, liver and metabolic diseases. Find out more at www.somalogic.com and follow @somalogic on LinkedIn.
Non-GAAP Financial Measures
We present non-GAAP financial measures in order to assist readers of our condensed consolidated financial statements in understanding the core operating results used by management to evaluate and run the business, as well as, for financial planning purposes. Our non-GAAP financial measure, Adjusted EBITDA, provides an additional tool for investors to use in comparing our financial performance over multiple periods.
Adjusted EBITDA is a key performance measure that our management uses to assess its operating performance. Adjusted EBITDA facilitates internal comparisons of our operating performance on a more consistent basis, and we use this measure for business planning, forecasting, and decision-making. We believe that Adjusted EBITDA enhances an investor’s understanding of our financial performance as it is useful in assessing our operating performance from period-to-period by excluding certain items that we believe are not representative of our core business.
Our Adjusted EBITDA may not be comparable to similarly titled measures of other companies because they may not calculate this measure in the same manner. Adjusted EBITDA is not prepared in accordance with GAAP and should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. When evaluating our performance, you should consider Adjusted EBITDA alongside other financial performance measures prepared in accordance with GAAP, including net loss.
Forward Looking Statements Disclaimer
This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements, other than statements of historical fact included in this press release, regarding our strategy, future operations, financial position, estimated revenues, projections, prospects, plans and objectives of management are forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “forecast,” “guidance,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “continue,” “will likely result,” “possible,” “potential,” “predict,” “pursue,” “target” and similar expressions, although not all forward-looking statements contain such identifying words. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Forward-looking statements do not guarantee future performance and involve known and unknown risks, uncertainties and other factors. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including factors which are beyond SomaLogic’s control. You should carefully consider these risks and uncertainties, including, but not limited to, those factors described under Part I, Item 1A – “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022, Part II, Item 1A – “Risk Factor” in our Quarterly Reports on Form 10-Q for the quarters ended June 30, 2023 and September 30, 2023, and other filings we make with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and SomaLogic assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Should one or more of these risks or uncertainties materialize, or should any of the assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The Company will not and does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
SomaLogic Contact
Emilia Costales
720-798-5054
ecostales@somalogic.com
Investor Contact
Marissa Bych
Gilmartin Group LLC
investors@somalogic.com
| SomaLogic, Inc. | |||||||||||||||
| Condensed Consolidated Statements of Operations and Comprehensive Loss | |||||||||||||||
| Unaudited | |||||||||||||||
| (in thousands, except share and per share amounts) | |||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||
| Revenue | |||||||||||||||
| Assay services revenue | $ | 17,866 | $ | 17,574 | $ | 52,882 | $ | 47,305 | |||||||
| Product revenue | 3,418 | 1,051 | 7,513 | 2,218 | |||||||||||
| Collaboration revenue | 763 | 763 | 2,288 | 2,288 | |||||||||||
| Other revenue | 1 | 22,325 | 212 | 27,026 | |||||||||||
| Total revenue | 22,048 | 41,713 | 62,895 | 78,837 | |||||||||||
| Operating expenses | |||||||||||||||
| Cost of assay services revenue | 9,994 | 11,264 | 31,353 | 29,215 | |||||||||||
| Cost of product revenue | 1,641 | 406 | 3,773 | 1,184 | |||||||||||
| Research and development | 10,458 | 19,419 | 35,340 | 50,855 | |||||||||||
| Selling, general and administrative | 23,880 | 49,511 | 87,642 | 116,024 | |||||||||||
| Transaction costs | 4,157 | 1,725 | 4,157 | 2,839 | |||||||||||
| Total operating expenses | 50,130 | 82,325 | 162,265 | 200,117 | |||||||||||
| Loss from operations | (28,082 | ) | (40,612 | ) | (99,370 | ) | (121,280 | ) | |||||||
| Other income | |||||||||||||||
| Interest income and other, net | 6,087 | 2,421 | 16,810 | 3,468 | |||||||||||
| Change in fair value of warrant liabilities | 316 | 3,371 | 1,896 | 30,547 | |||||||||||
| Change in fair value of earn-out liability | — | 1,260 | 15 | 26,749 | |||||||||||
| Total other income | 6,403 | 7,052 | 18,721 | 60,764 | |||||||||||
| Net loss before income tax (provision) benefit | $ | (21,679 | ) | $ | (33,560 | ) | $ | (80,649 | ) | $ | (60,516 | ) | |||
| Income tax (provision) benefit | (478 | ) | 618 | (482 | ) | 610 | |||||||||
| Net loss | $ | (22,157 | ) | $ | (32,942 | ) | $ | (81,131 | ) | $ | (59,906 | ) | |||
| Other comprehensive income (loss) | |||||||||||||||
| Net unrealized (loss) gain on available-for-sale securities | $ | (27 | ) | $ | (13 | ) | $ | 501 | $ | (874 | ) | ||||
| Foreign currency translation loss | (4 | ) | (14 | ) | (2 | ) | (28 | ) | |||||||
| Total other comprehensive (loss) income | (31 | ) | (27 | ) | 499 | (902 | ) | ||||||||
| Comprehensive loss | $ | (22,188 | ) | $ | (32,969 | ) | $ | (80,632 | ) | $ | (60,808 | ) | |||
| Net loss per share, basic and diluted | $ | (0.12 | ) | $ | (0.18 | ) | $ | (0.43 | ) | $ | (0.33 | ) | |||
| Weighted-average shares outstanding used to compute net loss per share, basic and diluted | 187,070,510 | 184,407,874 | 186,780,699 | 183,209,213 | |||||||||||
| SomaLogic, Inc. | |||||||
| Condensed Consolidated Balance Sheets | |||||||
| Unaudited | |||||||
| (in thousands, except share data) | |||||||
| September 30, 2023 | December 31, 2022 | ||||||
| ASSETS | |||||||
| Current assets | |||||||
| Cash and cash equivalents | $ | 305,571 | $ | 421,830 | |||
| Investments | 148,239 | 117,758 | |||||
| Accounts receivable, net | 20,730 | 17,006 | |||||
| Inventory | 13,884 | 13,897 | |||||
| Deferred costs of services | 379 | 1,337 | |||||
| Prepaid expenses and other current assets | 5,302 | 9,873 | |||||
| Total current assets | 494,105 | 581,701 | |||||
| Non-current inventory | 11,119 | 4,643 | |||||
| Accounts receivable, net of current portion | 8,681 | 9,284 | |||||
| Property and equipment, net of accumulated depreciation and amortization of $23,126 and $17,899 as of September 30, 2023 and December 31, 2022, respectively | 18,172 | 19,564 | |||||
| Other long-term assets | 5,872 | 5,083 | |||||
| Intangible assets | 16,700 | 16,700 | |||||
| Goodwill | 10,399 | 10,399 | |||||
| Total assets | $ | 565,048 | $ | 647,374 | |||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||
| Current liabilities | |||||||
| Accounts payable | $ | 11,458 | $ | 16,794 | |||
| Accrued liabilities | 10,829 | 20,678 | |||||
| Deferred revenue | 3,074 | 3,383 | |||||
| Other current liabilities | 2,420 | 2,477 | |||||
| Total current liabilities | 27,781 | 43,332 | |||||
| Warrant liabilities | 2,317 | 4,213 | |||||
| Deferred revenue, net of current portion | 30,944 | 31,732 | |||||
| Other long-term liabilities | 7,267 | 5,539 | |||||
| Total liabilities | 68,309 | 84,816 | |||||
| Commitments and contingencies | |||||||
| Stockholders’ equity | |||||||
| Preferred stock, $0.0001 par value; 1,000,000 shares authorized; no shares issued and outstanding at September 30, 2023 and December 31, 2022 | — | — | |||||
| Common stock, $0.0001 par value; 600,000,000 shares authorized; 188,662,349 and 187,647,973 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively | 19 | 19 | |||||
| Additional paid-in capital | 1,186,420 | 1,171,122 | |||||
| Accumulated other comprehensive income (loss) | (14 | ) | (513 | ) | |||
| Accumulated deficit | (689,686 | ) | (608,070 | ) | |||
| Total stockholders’ equity | 496,739 | 562,558 | |||||
| Total liabilities and stockholders’ equity | $ | 565,048 | $ | 647,374 | |||
| SomaLogic, Inc. | |||||||||||||||
| Reconciliation of net loss in accordance with GAAP to non-GAAP adjusted EBITDA | |||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| (in thousands) | 2023 | 2022 | 2023 | 2022 | |||||||||||
| Net loss | $ | (22,157 | ) | $ | (32,942 | ) | $ | (81,131 | ) | $ | (59,906 | ) | |||
| Adjustments to reconcile to EBITDA: | |||||||||||||||
| Interest income and other, net | (6,087 | ) | (2,421 | ) | (16,810 | ) | (3,468 | ) | |||||||
| Income tax provision (benefit) | 478 | (618 | ) | 482 | (610 | ) | |||||||||
| Depreciation and amortization | 3,790 | 1,172 | 5,544 | 2,890 | |||||||||||
| EBITDA | (23,976 | ) | (34,809 | ) | (91,915 | ) | (61,094 | ) | |||||||
| Adjustments to reconcile to Adjusted EBITDA: | |||||||||||||||
| Change in fair value of warrant liabilities (1) | (316 | ) | (3,371 | ) | (1,896 | ) | (30,547 | ) | |||||||
| Change in fair value of earn-out liability (2) | — | (1,260 | ) | (15 | ) | (26,749 | ) | ||||||||
| Stock compensation expense related to equity award modifications (3) | — | 7,538 | 1,224 | — | |||||||||||
| Restructuring charges (4) | — | — | 1,100 | — | |||||||||||
| Transaction costs(5) | 4,157 | 1,725 | 4,157 | 2,839 | |||||||||||
| Adjusted EBITDA | $ | (20,135 | ) | $ | (30,177 | ) | $ | (87,345 | ) | $ | (115,551 | ) | |||
| (1) | Represents change in fair value of warrant liabilities. |
| (2) | Represents change in fair value of earn-out liability. |
| (3) | Represents stock-based compensation expense related to equity award modifications that occurred separately from our Strategic Reorganization. |
| (4) | Represents restructuring charges related to the Strategic Reorganization consisting of severance costs, other termination benefit costs, and non-cash stock-based compensation expense. |
| (5) | Represents costs incurred related to mergers and acquisitions, primarily consisting of legal and advisory fees. |
